Approval based on MIRACLE Phase III trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improvement in asthma symptom control
Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
This development will position the company at the forefront of anti- malaria API production globally and is expected to drive substantial growth and profitability
This is in partnership with Mepro Pharmaceuticals which have successfully developed and commercialised the Albendazole Chewable formulation
These digital initiatives are expected to enhance the accessibility and efficiency of drug safety monitoring and standards compliance
Application based on the Transcend FL trial in which Breyanzi showed deep and durable responses and a consistent and well-established safety profile
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
Subscribe To Our Newsletter & Stay Updated
